Bio-Works reports first quarter 2026

Summary of the quarter

January – March 2026 (January – March 2025)

• Net sales for the first quarter amounted to 29.3 (9.0) MSEK, an increase of 20.3 MSEK. Sales growth has been strong during the quarter, particularly driven by large deliveries in Europe.
• Operating profit for the quarter amounted to 4.1 (-7.8) MSEK.
• Profit for the quarter was 4.7 (-8.0) MSEK.
• Cash flow for the period amounted to +6.3 (-4.4) MSEK
• Order intake for the first quarter totaled 15.5 (31.6) MSEK, a decrease of 16.1 MSEK (order value converted at the exchange rate at the time of order).
• Personnel costs amounted to 9.0 (7.9) MSEK. The increase in personnel costs is due to new hires and an increase in employees’ working hours.
• Other external costs totaled 8.5 (7.0) MSEK, the increase is mainly related to the higher sales during the quarter.
• Earnings per share (before dilution) were +0.05 (-0.10) SEK and earnings per share (after dilution) were +0.04 (-0.09) SEK.
• Cash and cash equivalents at the end of the period, as of March 31, amounted to 41.3 (29.7) MSEK.

Message from the CEO

Bio-Works has had a strong start to 2026, building on the momentum established in the previous year. 

Operating profit is developing positively, and the quarter was profitable. Our high gross margin means that increased sales have a clear impact on earnings, demonstrating the operational leverage in our business. Together with improved cash flow and a solid financial position, this provides us with good conditions to continue developing the company. 

Order intake varies between quarters, which is natural at our current stage. At the same time, we are seeing a positive trend in the form of larger deals and deeper customer relationships. 

Bio-Works’ efforts to position itself in the biopharmaceutical production chain are yielding results. Our products are increasingly becoming part of our customers’ processes, contributing to recurring business. This is an important part of our business model and our continued development. 

Our priorities going forward are to build on our global presence, increase the number of large customers, and maintain cost discipline. 

By continuing to gain market share in a growing market and strengthening its position with customers, Bio-Works will achieve the goal of sustainable profitable growth.

I would like to thank our customers, partners, employees, and shareholders for your continued trust. 

Lone Carlbom
CEO, Bio-Works Technologies AB

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: [email protected], phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.